HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Jiangsu Recbio Technology / Equity Capital Markets

In recent years, driven by global public health event such as COVID-19, vaccine R&amp;D and production have gradually attracted wide attention in the market. More and more vaccine companies have begun to develop innovative vaccines with the support of capital, and <a href="https://www.smartkarma.com/entities/jiangsu-recbio-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33810:1" rel="noopener">Jiangsu Recbio Technology (JRT HK)</a> is one of them. On July 16, 2021, Recbio submitted its prospectus to the HKEX for the application of listing on the main board. This insight mainly analyzed the industry characteristics, the pipeline and related concerns of the Company.

In recent years, driven by global public health event such as COVID-19, vaccine R&amp;D and production have gradually attracted wide attention in the market. More and more vaccine companies have begun to develop innovative vaccines with the support of capital, and Jiangsu Recbio Technology (JRT HK) is one of them. On July 16, 2021, Recbio submitted its prospectus to the HKEX for the application of listing on the main board. This insight mainly analyzed the industry characteristics, the pipeline and related concerns of the Company.

Pre-IPO Jiangsu Recbio Technology - There Are Many Uncertainties

The global spread of COVID-19 has given the vaccine industry unprecedented attention. With the increasing prosperity of the industry, many vaccine companies are increasingly enthusiastic about going public. On Sep 12, 2021, <a href="https://www.smartkarma.com/entities/aim-vaccine-co-ltd" target="_blank" data-smartkarma-citation="entities:33778:1" rel="noopener">AIM Vaccine (AIM HK)</a> submitted its listing application to the HKEX and officially started its IPO process. AIM is a leading vaccine company that covers the full value chain from R&amp;D to manufacturing and to commercialization. This insight mainly analyzed AIM in terms of the industry characteristics, the key vaccine products, the vaccine pipeline and related concerns of the Company.

The global spread of COVID-19 has given the vaccine industry unprecedented attention. With the increasing prosperity of the industry, many vaccine companies are increasingly enthusiastic about going public. On Sep 12, 2021, AIM Vaccine (AIM HK) submitted its listing application to the HKEX and officially started its IPO process. AIM is a leading vaccine company that covers the full value chain from R&amp;D to manufacturing and to commercialization. This insight mainly analyzed AIM in terms of the industry characteristics, the key vaccine products, the vaccine pipeline and related concerns of the Company.

Pre-IPO AIM Vaccine - Insights on Key Products, Pipeline and Concerns

Clover Biopharmaceuticals / Equity Capital Markets

On April 23, 2021, <a href="https://www.smartkarma.com/entities/clover-biopharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:33029:1" rel="noopener">Clover Biopharmaceuticals (CBL HK)</a> filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a>, Yu Dechao from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, Du Ying from <a href="https://www.smartkarma.com/entities/zai-lab-ltd" target="_blank" data-smartkarma-citation="entities:25877:1" rel="noopener">Zai Lab Ltd (ZLAB US)</a>, etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.

On April 23, 2021, Clover Biopharmaceuticals (CBL HK) filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from BeiGene Ltd (6160 HK), Yu Dechao from Innovent Biologics Inc (1801 HK), Du Ying from Zai Lab Ltd (ZLAB US), etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.

Pre-IPO Clover Biopharmaceuticals - Insights on the Core Technology and Product Candidates

China

Clover Biopharmaceuticals is a global commercial-stage biotechnology company focused on developing innovative vaccines and biologic therapeutic candidates. The company designs, tests, and manufactures biologic products using its protein engineering and cell-culture technology. Its pipeline includes vaccines for seasonal influenza, COVID-19, Respiratory Syncytial Virus (RSV), and pneumococcal conjugated vaccines (PCV), as well as therapeutic candidates for infectious diseases, cancer, and autoimmune diseases. Headquartered in Chengdu, China, the company was founded in 2007.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clover Biopharmaceuticals (2197 HK)

Pre-IPO Jiangsu Recbio Technology - There Are Many Uncertainties

This article mainly analyzed Recbio Technology in terms of the vaccine industry characteristics, core product candidates (HPV vaccines, COVID-19...

Xinyao (Criss) Wang

Pre-IPO AIM Vaccine - Insights on Key Products, Pipeline and Concerns

This article mainly analyzed AIM in terms of the vaccine industry characteristics, the key vaccine products (human rabies vaccine, recombinant HBV...

Xinyao (Criss) Wang

Pre-IPO Clover Biopharmaceuticals - Insights on the Core Technology and Product Candidates

The article analyzed Clover's core technology platform, COVID-19 vaccine and SCB-808 in pipeline,future challenge on competition and potential...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)